IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes
Latest Information Update: 04 Feb 2025
At a glance
- Drugs Anakinra (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms Cephalira
Most Recent Events
- 29 Jan 2025 Status changed from recruiting to discontinued.
- 04 Mar 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 04 Mar 2024 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2024.